Spyre TherapeuticsSYRE
Recorded

Spyre Therapeutics UBS Global Biopharma Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration30 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Alice NettletonAnalyst

Hi. Good afternoon, everybody. Welcome to the next session at the UBS Global Biopharma Conference. I'm Alice Nettleton, one of the SMID Biotech Analysts at UBS. Happy to introduce Spyre Therapeutics. We have with us Cameron Turtle, CEO. Thank you so much for joining us, Cameron.

Cameron TurtleCEO

Good to see you. Appreciate having us.

Alice NettletonAnalyst

So maybe just to level set for the audience, for people who might not be as familiar with the story, would you like to give a quick overview of Spyre, and then we can move to some Q&A?

Cameron TurtleCEO

Of course. Yeah. In general, our overall goal at Spyre is to create a set of products that raise the standard of care for serious autoimmune diseases. Our strategy is, I think, pretty straightforward, which is basically find what we believe are the best targets in the space, engineer antibodies that have optimized properties relative to what's out there today, and then combine them together in combination therapies in these markets. I think broadly in the disease spaces where we're playing, we've seen over the last few decades a lot of success in terms of new therapies that provide patients options, yet many of them hit what physicians call the therapeutic ceiling, where despite half dozen approved classes in IBD, for example, we don't do better than about a 25% placebo-adjusted remission rate.

Cameron TurtleCEO

For a disease that affects north of 2 million people in the U.S., I sincerely hope we can do better than that. I think we have increasing evidence over the last few years that combining multiple mechanisms is able to do that, which is not overly surprising given that these are heterogeneous diseases, so blocking multiple pathways has a good shot. We are working on that in inflammatory bowel disease and a dermatologic disease called HS, where we think these combinations can really elevate the standard of care.

Alice NettletonAnalyst

In IBD, you have a phase II POC trial ongoing in UC called SKYLINE, which is evaluating your long-acting alpha4beta7, IL-23, and TL1A as monotherapies as well as three combinations of those components. Can you remind us on a high level, what is the goal of this trial, what is the design, and what data have you shown so far from the part A portion?

Cameron TurtleCEO

Yeah. We think this is a very innovative and efficient study in IBD that we were really uniquely positioned for because we had this portfolio of these three long-acting antibodies at the same time. To develop a combination therapy, you need to show what is called contribution of components. The monotherapies need to beat placebo, and then the combinations need to beat their components. We could have run this as three separate combination studies, combo, mono, and placebo, but by running it as one platform study, we can have one shared placebo, each of the monotherapies once, and then all of the three combinations.

Cameron TurtleCEO

This lets us run a study, still very large, north of 600 patients, but it lets us test what I think may be the three best combinations in development, maybe the three best products overall, and do it in an efficient way where they have all the right comparators in a single study. I think now that we have clarified the timing of the readout next year, where we will share all of this in one large readout in the third quarter, I think it actually highlights how efficient this study was, because we started enrolling the second part of this study in April. We expect to be done enrolling it in the first quarter of next year to provide that readout in the third quarter, which means we have enrolled north of, we will be in, have enrolled north of 600 patients in less than 12 months.

Cameron TurtleCEO

Remarkably fast, I think indicates the level of enthusiasm for this study and this approach overall. Again, you mentioned it's a two-part study, and part A, that's what we've reported all the data for this year. This is just providing preliminary proof of concept that each of these monotherapies work as we expect. I think we showed that at least that good for our three monotherapies. I think our TL1A and our IL-23 performed like their class did, and then I think our alpha4beta7, SPY001, might have even exceeded that and looked like the higher dosing and target coverage that we provide with our molecule might actually improve from the first-generation alpha4 antibody.

Cameron TurtleCEO

That really is showing each of these monotherapies work the way they expect, though it really only sets up what we think is really the exciting readout next year of seeing what happens when we put them together.

Alice NettletonAnalyst

Mm-hmm. Is the maintenance data from part A important, and when should we expect that?

Cameron TurtleCEO

Yeah. The study is a treat-through design study, meaning that, at week 12, we look at what's called the induction dataset. That's what we reported this year. Then for each of these arms, it continues till week 48, which is the maintenance dataset that you're referring to. So for each of these cohorts, about nine months after we have the induction data, we'll get the maintenance datasets. However, for part A, I think the maintenance datasets, it's 40-odd patients per arm, three different maintenance datasets. We'll get the last one from our IL-23 kind of around the middle of the year, and I would expect kind of from that point or sometime thereafter at a medical conference, I expect we'll share all the maintenance datasets together for those three.

Cameron TurtleCEO

I would doubt there would be any major surprises in the maintenance data given what we know about each of these classes and how they perform from induction to maintenance.

Alice NettletonAnalyst

Okay. As you mentioned, you recently confirmed the part B combination readout would be in the third quarter of 2027, and this will be one big readout. Can you help us understand what will be included in this update, including the scope and the level of detail that you plan to disclose?

Cameron TurtleCEO

Yeah. I think it should be one of the most interesting readouts in IBD that has occurred for quite some time and going forward as well, where we're testing each of these combinations and their components head-to-head against each other. I think it will be one of the more interesting datasets we've seen. We plan to report them all out at the same time. Again, that's the efficiency of the design, to be able to compare them against each other and really help us prioritize really in what order we're going to be advancing products to phase III thereafter. The key result, the primary endpoint is clinical remission. So that's really what the primary determinant is. Of course, we'll look at a whole host of other secondary and exploratory endpoints as well, and of course, safety is key too.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day